Recardio announces conclusion of interim analysis of Phase 2 in AMI
Category: #health  By Pankaj Singh  Date: 2020-02-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Recardio announces conclusion of interim analysis of Phase 2 in AMI

 

  • The study of combination of dutogliptin and filgrastim involved approximately 120 patient enrollments.
  • The company expects the trial completion by year end.

Treatment trials across various pharmaceutical companies are on the go lately. Supporting the same, Recardio, one of the clinical stage life science companies, reportedly announced the completion of an interim analysis of its Phase 2 study of dutogliptin and filgrastim, combined, in early recovery post-myocardial infarction. Moreover, it has been estimated that the patient recruitment for the study is still continuing at all the participating centers of the company.

The placebo-controlled Phase 2 study is expected to enroll nearly 120 patients globally. Apparently, the study is planned to evaluate the efficiency and safety of the company’s dutogliptin, which is used to restore the dropped myocardial function in patients experiencing severe heart attack and percutaneous coronary intervention.

Further, the analysis was carried out in agreement with the analysis’ Data Safety Monitoring Board, which produced an authentication of the study and its continuation, prompting participating trial centers to carry on their patient recruitment operations, globally. 

Speaking on the completion of the analysis, Recardio’s Executive Chairman, Roman Schenk reportedly quoted that the interim analysis has been a crucial milestone for completion of the study. The company is highly encouraged by the efforts of several clinical investigators and is determined to conclude the trial by this year end.

It has been reported that Recardio’s regenerative therapeutic approach to reduce and repair heart muscle injury constitutes recruiting, mobilizing, and homing stem cells in-vivo by making use of cytokines and inhibitors.

Headquartered in California, Recardio Inc., is a clinical stage life science company which focuses on therapies involving the cardiovascular, oncology, and infectious disorders. The company’s lead drug, dutogliptin has demonstrated considerable effects in activating vivid chemokines essential for treatment of different cardiovascular diseases.

Source credits: https://recardio.eu/2020/02/recardio-completes-interim-analysis-of-phase-2-in-ami/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...